Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly

Clinical Endocrinology

Volumn 77, Issue 3, 2012, Pages 430-438

  Lin, E ^a   Wexler, T L ^a   Nachtigall, L ^a   Tritos, N ^a   Swearingen, B ^a   Hemphill, L ^a   Loeffler, J ^a   Biller, B M K ^a   Klibanski, A ^a   Miller, K K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GLUCOCORTICOID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ABDOMINAL FAT; ABDOMINAL SUBCUTANEOUS FAT; ACROMEGALY; ADRENAL INSUFFICIENCY; ADULT; AGED; ARTERIAL PRESSURE; ARTERIAL WALL THICKNESS; ARTICLE; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY EXPENDITURE; FEMALE; GROWTH HORMONE DEFICIENCY; HOMEOSTASIS; HUMAN; HYPOGONADISM; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TOTAL BODY WATER;

ACROMEGALY; ADRENAL INSUFFICIENCY; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY COMPOSITION; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INFLAMMATION MEDIATORS; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84865031669     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04361.x     Document Type: Article

References (38)

1. Dekkers, O.M., Biermasz, N.R., Pereira, A.M., et al,. (2008) Mortality in acromegaly: a metaanalysis. Journal of Clinical Endocrinology and Metabolism, 93, 61-67.
2. Clayton, R.N., (2003) Cardiovascular function in acromegaly. Endocrine Reviews, 24, 272-277.
3. Swearingen, B., Barker, F.G. 2nd, Katznelson, L., et al,. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419-3426.
4. Holdaway, I.M., Bolland, M.J., &, Gamble, G.D., (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology, 159, 89-95.
5. Sesmilo, G., Fairfield, W.P., Katznelson, L., et al,. (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. Journal of Clinical Endocrinology and Metabolism, 87, 1692-1699.
6. Cohen, R., Chanson, P., Bruckert, E., et al,. (1992) Effects of octreotide on lipid metabolism in acromegaly. Hormone and Metabolic Research, 24, 397-400.
7. Colao, A., Marzullo, P., &, Lombardi, G., (2002) Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. European Journal of Endocrinology, 146, 303-309.
8. Oscarsson, J., Wiklund, O., Jakobsson, K.E., et al,. (1994) Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy. Clinical Endocrinology, 41, 603-608.
9. Ronchi, C.L., Giavoli, C., Ferrante, E., et al,. (2009) Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments. European Journal of Endocrinology, 161, 37-42.
10. Weaver, J.U., Monson, J.P., Noonan, K., et al,. (1995) The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism, 80, 153-159.
11. Johansson, J.O., Fowelin, J., Landin, K., et al,. (1995) Growth hormone-deficient adults are insulin-resistant. Metabolism, 44, 1126-1129.
12. Rosen, T., Eden, S., Larson, G., et al,. (1993) Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinologica, 129, 195-200.
13. Pfeifer, M., Verhovec, R., Zizek, B., et al,. (1999) Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 84, 453-457.
14. Sesmilo, G., Miller, K.K., Hayden, D., et al,. (2001) Inflammatory cardiovascular risk markers in women with hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 86, 5774-5781.
15. Devin, J.K., Blevins Jr, L.S., Verity, D.K., et al,. (2007) Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism, 92, 3633-3639.
16. Jorgensen, J.O., Pedersen, S.A., Thuesen, L., et al,. (1989) Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet, 1, 1221-1225.
17. Beauregard, C., Utz, A.L., Schaub, A.E., et al,. (2008) Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 93, 2063-2071.
18. Cuneo, R.C., Judd, S., Wallace, J.D., et al,. (1998) The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 83, 107-116.
19. Bengtsson, B.A., Eden, S., Lonn, L., et al,. (1993) Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. Journal of Clinical Endocrinology and Metabolism, 76, 309-317.
20. Baum, H.B., Biller, B.M., Finkelstein, J.S., et al,. (1996) Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Annals of Internal Medicine, 125, 883-890.
21. Maison, P., Griffin, S., Nicoue-Beglah, M., et al,. (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. Journal of Clinical Endocrinology and Metabolism, 89, 2192-2199.
22. Salomon, F., Cuneo, R.C., Hesp, R., et al,. (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. New England Journal of Medicine, 321, 1797-1803.
23. Sesmilo, G., Biller, B.M., Llevadot, J., et al,. (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Annals of Internal Medicine, 133, 111-122.
24. Bollerslev, J., Ueland, T., Jorgensen, A.P., et al,. (2006) Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. European Journal of Endocrinology, 154, 537-543.
25. Johansson, J.O., Landin, K., Johannsson, G., et al,. (1996) Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thrombosis and Haemostasis, 76, 422-428.
26. Hartman, M.L., Crowe, B.J., Biller, B.M., et al,. (2002) Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? Journal of Clinical Endocrinology and Metabolism, 87, 477-485.
27. Miller, K.K., Wexler, T., Fazeli, P., et al,. (2010) Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. Journal of Clinical Endocrinology and Metabolism, 95, 567-577.
28. Wexler, T., Gunnell, L., Omer, Z., et al,. (2009) Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. Journal of Clinical Endocrinology and Metabolism, 94, 2471-2477.
29. Wexler, T.L., Durst, R., McCarty, D., et al,. (2010) Growth hormone status predicts left ventricular mass in patients after cure of acromegaly. Growth Hormone IGF Research, 20, 333-337.
30. Hayter, A., (1986) The maximum familywise error rate of fisher's least significant difference test. Journal of the American Statistical Association, 81, 1000-1004.
31. Corneli, G., Di Somma, C., Baldelli, R., et al,. (2005) The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. European Journal of Endocrinology, 153, 257-264.
32. Feldt-Rasmussen, U., Abs, R., Bengtsson, B.A., et al,. (2002) Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. European Journal of Endocrinology, 146, 67-74.
33. Norrman, L.L., Johannsson, G., Sunnerhagen, K.S., et al,. (2008) Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. Journal of Clinical Endocrinology and Metabolism, 93, 2531-2538.
34. van der Klaauw, A.A., Bax, J.J., Roelfsema, F., et al,. (2009) Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. Pituitary, 12, 339-346.
35. Yamada, S., Fukuhara, N., Nishioka, H., et al,. (2011) Growth hormone deficiency in patients after cure of acromegaly by surgery alone. European Journal of Endocrinology, 165, 873-879.
36. Sonksen, P.H., Greenwood, F.C., Ellis, J.P., et al,. (1967) Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. Journal of Clinical Endocrinology and Metabolism, 27, 1418-1430.
37. Hew, F.L., Koschmann, M., Christopher, M., et al,. (1996) Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. Journal of Clinical Endocrinology and Metabolism, 81, 555-564.
38. Holdaway, I.M., Rajasoorya, R.C., &, Gamble, G.D., (2004) Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 667-674.